Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Subscribe To Our Newsletter & Stay Updated
